Malignant hyperthermia

Korean Journal of Anesthesiology

Volumn 63, Issue 5, 2012, Pages 391-401

  Kim, Dong Chan ^a  

^a Chonbuk National University Medical School   (South Korea)

Author keywords

Diagnosis; Epidemiology; Malignant hyperthermia; Pathophysiology; Treatment

Indexed keywords

DANTROLENE; RYANODINE RECEPTOR;

ACIDOSIS; CAPNOGRAPHY; CLINICAL FEATURE; END TIDAL CARBON DIOXIDE TENSION; GENE MUTATION; HUMAN; HYPERTHERMIA; KOREA; LABORATORY TEST; MALIGNANT HYPERTHERMIA; MOLECULAR GENETICS; MUSCLE CONTRACTURE; MUSCLE RIGIDITY; NEUROMUSCULAR DISEASE; PATHOPHYSIOLOGY; REVIEW; SKELETAL MUSCLE; TACHYCARDIA;

EID: 84870512870     PISSN: 20056419     EISSN: 20057563     Source Type: Journal    
DOI: 10.4097/kjae.2012.63.5.391     Document Type: Review

References (105)

1. Hirshey Dirksen SJ, Larach MG, Rosenberg H, Brandom BW, Parness J, Lang RS, et al. Future directions in malignant hyperthermia research and patient care. Anesth Analg 2011; 113: 1108-19.
2. Wappler F. Malignant hyperthermia. Eur J Anaesthesiol 2001; 18: 632-52.
3. Monnier N, Krivosic-Horber R, Payen JF, Kozak-Ribbens G, Nivoche Y, Adnet P, et al. Presence of two different genetic traits in malignant hyperthermia families: implication for genetic analysis, diagnosis, and incidence of malignant hyperthermia susceptibility. Anesthesiology 2002; 97: 1067-74.
4. Bachand M, Vachon N, Boisvert M, Mayer FM, Chartrand D. Clinical reassessment of malignant hyperthermia in Abitibi-Temiscamingue. Can J Anaesth 1997; 44: 696-701.
5. Wappler F. Anesthesia for patients with a history of malignant hyperthermia. Curr Opin Anaesthesiol 2010; 23: 417-22.
6. Britt BA, Kalow W. Malignant hyperthermia: a statistical review. Can Anaesth Soc J 1970; 17: 293-315.
7. Rosenberg H, Davis M, James D, Pollock N, Stowell K. Malignant hyperthermia. Orphanet J Rare Dis 2007; 2: 21.
8. Larach MG, Gronert GA, Allen GC, Brandom BW, Lehman EB. Clinical presentation, treatment, and complications of malignant hyperthermia in North America from 1987 to 2006. Anesth Analg 2010; 110: 498-507.
9. Rosero EB, Adesanya AO, Timaran CH, Joshi GP. Trends and outcomes of malignant hyperthermia in the United States, 2000 to 2005. Anesthesiology 2009; 110: 89-94.
10. Chamley D, Pollock NA, Stowell KM, Brown RL. Malignant hyperthermia in infancy and identification of a novel RYR1 mutation. Br J Anaesth 2000; 84: 500-4.
11. Ording H. Investigation of malignant hyperthermia susceptibility in Denmark. Dan Med Bull 1996; 43: 111-25.
12. Robinson RL, Curran JL, Ellis FR, Halsall PJ, Hall WJ, Hopkins PM, et al. Multiple interacting gene products may influence susceptibility to malignant hyperthermia. Ann Human Genet 2000; 64: 307-20.
13. Hernandez JF, Secrest JA, Hill L, McClarty SJ. Scientific advances in the genetic understanding and diagnosis of malignant hyperthermia. J Perianesth Nurs 2009; 24: 19-31.
14. Brady JE, Sun LS, Rosenberg H, Li G. Prevalence of malignant hyperthermia due to anesthesia in New York State, 2001-2005. Anesth Analg 2009; 109: 1162-6.
15. Iaizzo PA, Klein W, Lehmann-Horn F. Fura-2 detected myoplasmic calcium and its correlation with contracture force in skeletal muscle from normal and malignant hyperthermia susceptible pigs. Pflugers Arch 1988; 411: 648-53.
16. Struk A, Lehmann-Horn F, Melzer W. Voltage-dependent calcium release in human malignant hyperthermia muscle fibers. Biophys J 1998; 75: 2402-10.
17. 2+ release from sarcoplasmic reticulum of malignant hyperthermia susceptible pigs. Biochim Biophys Acta 1991; 1064: 175-83.
18. Yang T, Allen PD, Pessah IN, Lopez JR. Enhanced excitation-coupled calcium entry in myotubes is associated with expression of RyR1 malignant hyperthermia mutations. J Biol Chem 2007; 282: 37471-8.
19. 2+ release by skeletal muscle sarcoplasmic reticulum: differing sensitivity to inhalational anesthetics. Anesthesiology 1988; 69: 571-7.
20. 2+ channel activity. J Bioenerg Biomembr 1989; 21: 227-46.
21. 2+ release from sarcoplasmic reticulum of normal and malignant hyperthermia susceptible pig muscles. Biochim Biophys Acta 1988; 945: 246-52.
22. Fill M, Coronado R, Mickelson JR, Vilven J, Ma JJ, Jacobson BA, et al. Abnormal ryanodine receptor channels in malignant hyperthermia. Biophys J 1990; 57: 471-5.
23. ++ regulatory site defect in sarcoplasmic reticulum from malignant hyperthermia pig muscle. J Pharmacol Exp Ther 1991; 256: 645-9.
24. McCarthy TV, Quane KA, Lynch PJ. Ryanodine receptor mutations in malignant hyperthermia and central core disease. Hum Mutat 2000; 15: 410-7.
25. Maclennan DH, Zvaritch E. Mechanistic models for muscle diseases and disorders originating in the sarcoplasmic reticulum. Biochim Biophys Acta 2011; 1813: 948-64.
26. Robinson R, Carpenter D, Shaw MA, Halsall J, Hopkins P. Mutations in RYR1 in malignant hyperthermia and central core disease. Hum Mutat 2006; 27: 977-89.
27. Sambuughin N, Holley H, Muldoon S, Brandom BW, de Bantel AM, Tobin JR, et al. Screening of the entire ryanodine receptor type 1 coding region for sequence variants associated with malignant hyperthermia susceptibility in the north American population. Anesthesiology 2005; 102: 515-21.
28. Brandom BW. Genetics of malignant hyperthermia. Sci World J 2006; 6: 1722-30.
29. Monnier N, Procaccio V, Stieglitz P, Lunardi J. Malignant-hyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive l-type voltage-dependent calcium-channel receptor in skeletal muscle. Am J Hum Genet 1997; 60: 1316-25.
30. Marchant CL, Ellis FR, Halsall PJ, Hopkins PM, Robinson RL. Mutation analysis of two patients with hypokalemic periodic paralysis and suspected malignant hyperthermia. Muscle Nerve 2004; 30: 114-7.
31. Hopkins PM. Malignant hyperthermia: advances in clinical management and diagnosis. Br J Anaesth 2000; 85: 118-28.
32. Litman RS, Rosenberg H. Malignant hyperthermia: update on susceptibility testing. JAMA 2005; 293: 2918-24.
33. Iaizzo PA, Kehler CH, Carr RJ, Sessler DI, Belani KG. Prior hypothermia attenuates malignant hyperthermia in susceptible swine. Anesth Analg 1996; 82: 803-9.
34. Levitt RC, Nouri N, Jedlicka AE, McKusick VA, Marks AR, Shutack JG, et al. Evidence for genetic heterogeneity in malignant hyperthermia susceptibility. Genomics 1991; 11: 543-7.
35. Bandschapp O, Girard T. Malignant hyperthermia. Swiss Med Wkly 2012; 142: w13652.
36. Heffron JJ. Malignant hyperthermia: biochemical aspects of the acute episode. Br J Anaesth 1988; 60: 274-8.
37. Kim DC, Lim HR, Han YJ. Early recognition of malignant hyperthermia with capnography: A case report. Korean J Anesthesiol 2002; 43: 667-72.
38. Tautz TJ, Urwyler A, Antognini JF, Riou B. Case scenario: Increased end-tidal carbon dioxide: a diagnostic dilemma. Anesthesiology 2010; 112: 440-6.
39. Karan SM, Crowl F, Muldoon SM. Malignant hyperthermia masked by capnographic monitoring. Anesth Analg 1994; 78: 590-2.
40. Denborough MA. Anaesthetic deaths in a family (letter). Lancet 1960; 2: 45.
41. Ali SZ, Taguchi A, Rosenberg H. Malignant hyperthermia. Best Pract Res Clin Anaesthesiol 2003; 17: 519-33.
42. Nelson TE. Porcine malignant hyperthermia: critical temperatures for in vivo and in vitro responses. Anesthesiology 1990; 73: 449-54.
43. DI. Temperature monitoring and perioperative thermoregulation. Anesthesiology 2008; 109: 318-38.
44. Stratman RC, Flynn JD, Hatton KW. Malignant hyperthermia: a pharmacogenetic disorder. Orthopedics 2009; 32: 835.
45. Larach MG, Brandom BW, Allen GC, Gronert GA, Lehman EB. Cardiac arrests and deaths associated with malignant hyperthermia in North America from 1987 to 2006: a report from the north American malignant hyperthermia registry of the malignant hyperthermia association of the United States. Anesthesiology 2008; 108: 603-11.
46. Larach MG, Localio AR, Allen GC, Denborough MA, Ellis FR, Gronert GA, et al. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology 1994; 80: 771-9.
47. Von Richthofen V, Wappler F, Scholz J, Fiege M, Schulte am Esch J. Evaluation of malignant hyperthermia episodes with the Clinical Grading Scale. Anasthesiol Intensivmed Notfallmed Schmerzther 1998; 33: 244-9.
48. Lee JW, Moon SS, Lee JR, Kim DC. Reevaluation by clinical grading scale for malignant hyperthermia reported in Korean Journal of Anesthesiology. Korean J Anesthesiol 2008; 54: 640-5.
49. Larach MG, MacLennan DH. How carefully can we phenotype patients suspected of malignant hyperthermia susceptibility? Anesthesiology 1999; 90: 645-8.
50. Kalow W, Britt BA, Terreau ME, Haist C. Metabolic error of muscle metabolism after recovery from malignant hyperthermia. Lancet 1970; 2: 895-8.
51. Ellis FR, Harriman DG, Keaney NP, Kyei-Mensah K, Tyrrell JH. Halothane-induced muscle contracture as a cause of hyperpyrexia. Br J Anaesth 1971; 43: 721-2.
52. A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. The Malignant Hyperpyrexia Group. Br J Anaesth 1984; 56: 1267-9.
53. Larach MG. Standardization of the caffeine halothane muscle contracture test. North American Malignant Hyperthermia Group. Anesth Analg 1989; 69: 511-5.
54. Fletcher JE, Conti PA, Rosenberg H. Comparison of North American and European malignant hyperthermia group halothane contracture testing protocols in swine. Acta Anaesthesiol Scand 1991; 35: 483-7.
55. Allen GC, Larach MG, Kunselman AR. The sensitivity and specificity of the caffeine-halothane contracture test: a report from the North American Malignant Hyperthermia Registry. The North American Malignant Hyperthermia Registry of MHAUS. Anesthesiology 1998; 88: 579-88.
56. Ording H, Brancadoro V, Cozzolino S, Ellis FR, Glauber V, Gonano EF, et al. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group. Acta Anaesthesiol Scand 1997; 41: 955-66.
57. Fletcher JE, Rosenburg H, Aggarwal M. Comparison of European and North American malignant hyperthermia diagnostic protocol outcomes for use in genetic studies. Anesthesiology 1999; 90: 654-61.
58. Ording H, Bendixen D. Sources of variability in halothane and caffeine contracture tests for susceptibility to malignant hyperthermia. Eur J Anaesthesiol 1992; 9: 367-76.
59. Nelson TE, Rosenberg H, Muldoon SM. Genetic testing for malignant hyperthermia in North America. Anesthesiology 2004; 100: 212-4.
60. Urwyler A, Deufel T, McCarthy T, West S. Guidelines for molecular genetic detection of susceptibility to malignant hyperthermia. Br J Anaesth 2001; 86: 283-7.
61. Rosenberg H, Rueffert H. Clinical utility gene card for: malignant hyperthermia. Eur J Hum Genet 2011;19.
62. Girard T, Treves S, Voronkov E, Siegemund M, Urwyler A. Molecular genetic testing for malignant hyperthermia susceptibility. Anesthesiology 2004; 100: 1076-80.
63. McCarthy TV, Healy JM, Heffron JJ, Lehane M, Deufel T, Lehmann-Horn F, et al. Localization of the malignant hyperthermia susceptibility locus to human chromosome 19q12-13.2. Nature 1990; 343: 562-4.
64. Rosenberg H, Sambuughin N, Dirksen R. Malignant hyperthermia susceptibility. In: GeneReviews at GeneTests: Medical Genetics Information Resource database online. Seattle: University of Washington, 1997-2011. Updated January 19, 2010. Available at http://www.genetests.org. [Accessed August 1, 2012].
65. Deufel T, Sudbrak R, Feist Y, Rübsam B, Du Chesne I, Schäfer KL, et al. Discordance, in a malignant hyperthermia pedigree, between in vitro contracture-test phenotypes and haplotypes for the MHS1 region on chromosome 19q12-13.2, comprising the C1840T transition in the RYR1 gene. Am J Hum Genet 1995; 56: 1334-42.
66. MacLennan DH. Discordance between phenotype and genotype in malignant hyperthermia. Curr Opin Neurol 1995; 8: 397-401.
67. Robinson R, Hopkins P, Carsana A, Gilly H, Halsall J, Heytens L, et al. Several interacting genes influence the malignant hyperthermia phenotype. Hum Genet 2003; 112: 217-8.
68. Robinson RL, Anetseder MJ, Brancadoro V, van Broekhoven C, Carsana A, Censier K, et al. Recent advances in the diagnosis of malignant hyperthermia susceptibility: how confident can we be of genetic testing? Eur J Hum Genet 2003; 11: 342-8.
69. Robinson RL, Anetseder MJ, Brancadoro V, van Broekhoven C, Carsana A, Censier K, et al. Recent advances in the diagnosis of malignant hyperthermia susceptibility: how confident can we be of genetic testing? Eur J Hum Genet 2003; 11: 342-8.
70. Glahn KP, Ellis FR, Halsall PJ, Müller CR, Snoeck MM, Urwyler A, et al. Recognizing and managing a malignant hyperthermia crisis: guidelines from the European Malignant Hyperthermia Group. Br J Anaesth 2010; 105: 417-20.
71. Inan S, Wei H. The cytoprotective effects of dantrolene: a ryanodine receptor antagonist. Anesth Analg 2010; 111: 1400-10.
72. Krause T, Gerbershagen MU, Fiege M, Weisshorn R, Wappler F. Dantrolene-- a review of its pharmacology, therapeutic use and new developments. Anaesthesia 2004; 59: 364-73.
73. Kurihara T, Brooks JE. Excitation-contraction uncoupling. The effect of hyperosomolar glycerol solution and dantrolene sodium on mammalian muscle in vitro. Arch Neurol 1975; 32: 92-7.
74. Bosch X, Poch E, Grau JM. Rhabdomyolysis and acute kidney injury. N Engl J Med 2009; 361: 62-72.
75. Burkman JM, Posner KL, Domino KB. Analysis of the clinical variables associated with recrudescence after malignant hyperthermia reactions. Anesthesiology 2007; 106: 901-6.
76. Afifi AK. Idiopathic hyperCKemia revisited. J Child Neurol 1998; 13: 251-2.
77. Sunohara N, Takagi A, Nonaka I, Sugita H, Satoyoshi E. Idiopathic hyperCKemia. Neurology 1984; 34: 544-7.
78. Prelle A, Tancredi L, Sciacco M, Chiveri L, Comi GP, Battistel A, et al. Retrospective study of a large population of patients with asymptomatic or minimally symptomatic raised serum creatine kinase levels. J Neurol 2002; 249: 305-11.
79. Simmons Z, Peterlin BL, Boyer PJ, Towfighi J. Muscle biopsy in the evaluation of patients with modestly elevated creatine kinase levels. Muscle Nerve 2003; 27: 242-4.
80. Capasso M, De Angelis MV, Di Muzio A, Scarciolla O, Pace M, Stuppia L, et al. Familial idiopathic hyper-CKemia: an underrecognized condition. Muscle Nerve 2006; 33: 760-5.
81. Ellis FR, Clarke IM, Modgill M, Currie S, Harriman DG. Evaluation of creatinine phosphokinase in screening patients for malignant hyperpyrexia. Br Med J 1975; 3: 511-3.
82. Paasuke RT, Brownell AK. Serum creatine kinase level as a screening test for susceptibility to malignant hyperthermia. JAMA 1986; 255: 769-71.
83. Lingaraju N, Rosenberg H. Unexplained increases in serum creatine kinase levels: its relation to malignant hyperthermia susceptibility. Anesth Analg 1991; 72: 702-5.
84. Weglinski MR, Wedel DJ, Engel AG. Malignant hyperthermia testing in patients with persistently increased serum creatine kinase levels. Anesth Analg 1997; 84: 1038-41.
85. Malandrini A, Orrico A, Gaudiano C, Gambelli S, Galli L, Berti G, et al. Muscle biopsy and in vitro contracture test in subjects with idiopathic hyperCKemia. Anesthesiology 2008; 109: 625-8.
86. Kasi PM. Malignant Hyperthermia and Idiopathic HyperCKemia. Case Report Med 2011; 2011: 194296.
87. Monnier N, Kozak-Ribbens G, Krivosic-Horber R, Nivoche Y, Qi D, Kraev N, et al. Correlations between genotype and pharmacological, histological, functional, and clinical phenotypes in malignant hyperthermia susceptibility. Hum Mutat 2005; 26: 413-25.
88. Davis PJ, Brandom BW. The association of malignant hyperthermia and unusual disease: when you're hot you're hot, or maybe not. Anesth Analg 2009; 109: 1001-3.
89. Klingler W, Rueffert H, Lehmann-Horn F, Girard T, Hopkins PM. Core myopathies and risk of malignant hyperthermia. Anesth Analg 2009; 109: 1167-73.
90. Benca J, Hogan K. Malignant hyperthermia, coexisting disorders, and enzymopathies: risks and management options. Anesth Analg 2009; 109: 1049-53.
91. Quinlivan RM, Muller CR, Davis M, Laing NG, Evans GA, Dwyer J, et al. Central core disease: clinical, pathological, and genetic features. Arch Dis Child 2003; 88: 1051-5.
92. Frank JP, Harati Y, Butler IJ, Nelson TE, Scott CI. Central core disease and malignant hyperthermia syndrome. Ann Neurol 1980; 7: 11-7.
93. Jungbluth H. Central core disease. Orpha J Rare Dis 2007; 2: 25.
94. Wu S, Ibarra MC, Malicdan MC, Murayama K, Ichihara Y, Kikuchi H, et al. Central core disease is due to RYR1 mutations in more than 90% of patients. Brain 2006; 129: 1470-80.
95. Jungbluth H. Multi-minicore disease. Orpha J Rare Dis 2007; 2: 31.
96. Jungbluth H, Zhou H, Hartley L, Halliger-Keller B, Messina S, Longman C, et al. Minicore myopathy with ophthalmoplegia caused by mutations in the ryanodine receptor type 1 gene. Neurology 2005; 65: 1930-5.
97. Ferreiro A, Quijano-Roy S, Pichereau C, Moghadaszadeh B, Goemans N, Bonnemann C, et al. Mutations of the selenoprotein N gene, which is implicated in rigid spine muscular dystrophy, cause the classical phenotype of multiminicore disease: reassessing the nosology of early-onset myopathies. Am J Hum Genet 2002; 71: 739-49.
98. Koch BM, Bertorini TE, Eng GD, Boehm R. Severe multicore disease associated with reaction to anaesthesia. Arch Neurol 1985; 42: 1204-6.
99. Jeong SK, Kim DC, Cho YG, Sunwoo IN, Kim DS. A double mutation of the ryanodine receptor type 1 gene in a malignant hyperthermia family with multiminicore myopathy. J Clin Neurol 2008; 4: 123-30.
100. King JO, Denborough MA. Anaesthetic-induced malignant hyperpyrexia in children. J Pediatr 1973; 83: 37-40.
101. Isaacs H, Badenhorst ME. Dominantly inherited malignant hyperthermia (MH) in the King-Denborough syndrome. Muscle Nerve 1992; 15: 740-2.
102. D'Arcy CE, Bjorksten A, Yiu EM, Bankier A, Gillies R, McLean CA, et al. King-Denborough syndrome caused by a novel mutation in the ryanodine receptor gene. Neurology 2008; 71: 776-7.
103. Kim DC, Kim DS. Identification of G7304A mutation in the ryanodine receptor type 1 gene in a patient with malignant hyperthermia and an extended pedigree study in a korean malignant hyperthermia family. Korean J Anesthesiol 2003; 44: 56-64.
104. Lee H, Kim DC, Lee JH, Cho YG, Lee HS, Choi SI, et al. Molecular genetic analysis of the ryanodine receptor gene (RYR1) in Korean malignant hyperthermia families. Korean J Lab Med 2010; 30: 702-10.
105. Lee JW, Moon SS, Lee JR, Kim DC. Reevaluation by clinical grading scale for malignant hyperthermia reported in Korean journal of anesthesiology. Korean J Anesthesiol 2008; 54: 640-5.